Genetic predisposition to ductal carcinoma in situ of the breast

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Petridis, Christos ^a   Brook, Mark N ^b   Shah, Vandna ^a   Kohut, Kelly ^c   Gorman, Patricia ^c   Caneppele, Michele ^c   Levi, Dina ^a   Papouli, Efterpi ^a   Orr, Nick ^b   Cox, Angela ^d   Cross, Simon S ^d   dos Santos Silva, Isabel ^e   Peto, Julian ^e   Swerdlow, Anthony ^b   Schoemaker, Minouk J ^b   Bolla, Manjeet K ^f   Wang, Qin ^f   Dennis, Joe ^f   Michailidou, Kyriaki ^f   Benitez, Javier ^g,h   González Neira, Anna ^g   Tessier, Daniel C ⁱ   Vincent, Daniel ⁱ   Li, Jingmei ^j   Figueroa, Jonine ^k   Kristensen, Vessela ^l,m,n   Borresen Dale, Anne Lise ^l,m   Soucy, Penny ^o   Simard, Jacques ^o   Milne, Roger L ^p,q   Giles, Graham G ^p,q   Margolin, Sara ^j   Lindblom, Annika ^j   Brüning, Thomas ^r   Brauch, Hiltrud ^s,t,u   Southey, Melissa C ^v   Hopper, John L ^q   Dörk, Thilo ^w   Bogdanova, Natalia V ^w   Kabisch, Maria ^u   Hamann, Ute ^u   Schmutzler, Rita K ^x   Meindl, Alfons ^y   Brenner, Hermann ^u   Arndt, Volker ^u   Winqvist, Robert ^z,aa   Pylkäs, Katri ^z,aa   Fasching, Peter A ^ab,ac   Beckmann, Matthias W ^ab   Lubinski, Jan ^ad   Jakubowska, Anna ^ad   Mulligan, Anna Marie ^ae,af   Andrulis, Irene L ^ag,ah   Tollenaar, Rob A E M ^ai   Devilee, Peter ^ai   Le Marchand, Loic ^aj   Haiman, Christopher A ^ak   Mannermaa, Arto ^al,am   Kosma, Veli Matti ^al,am   Radice, Paolo ^an   Peterlongo, Paolo ^ao   Marme, Frederik ^ap   Burwinkel, Barbara ^u,ap   van Deurzen, Carolien H M ^aq   Hollestelle, Antoinette ^ar   Miller, Nicola ^as   Kerin, Michael J ^as   Lambrechts, Diether ^at,au   Floris, Giuseppe ^av   Wesseling, Jelle ^aw   Flyger, Henrik ^ax   Bojesen, Stig E ^ax,ay   Yao, Song ^az   Ambrosone, Christine B ^az   Chenevix Trench, Georgia ^ba   Truong, Thérèse ^bb,bc   Guénel, Pascal ^bb,bc   Rudolph, Anja ^u   Chang Claude, Jenny ^u   Nevanlinna, Heli ^bd   Blomqvist, Carl ^bd   Czene, Kamila ^j   Brand, Judith S ^j   Olson, Janet E ^be   Couch, Fergus J ^be   Dunning, Alison M ^f   Hall, Per ^j   Easton, Douglas F ^f   Pharoah, Paul D P ^f   Pinder, Sarah E ^a   Schmidt, Marjanka K ^aw   Tomlinson, Ian ^bf   Roylance, Rebecca ^c   García Closas, Montserrat ^b,k   Sawyer, Elinor J ^a   more..

^a GUY S HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g Structural Biology and Biocomputing Programme   (Spain)

^h Centro de Investigación en Red de Enfermedades Raras   (Spain)

ⁱ MCGILL UNIVERSITY   (Canada)

^j KAROLINSKA INSTITUTE   (Sweden)

^k NATIONAL CANCER INSTITUTE   (United States)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF OSLO   (Norway)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o LAVAL UNIVERSITY   (Canada)

^p CANCER EPIDEMIOLOGY CENTRE   (Australia)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r RUHR UNIVERSITY BOCHUM   (Germany)

^s DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^t UNIVERSITY OF TÜBINGEN   (Germany)

^u GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^v UNIVERSITY OF MELBOURNE   (Australia)

^w HANNOVER MEDICAL SCHOOL   (Germany)

^x UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^y TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^z UNIVERSITY OF OULU   (Finland)

^aa Northern Finland Laboratory Centre NordLab   (Finland)

^ab UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad POMERANIAN MEDICAL UNIVERSITY   (Poland)

^ae UNIVERSITY OF TORONTO   (Canada)

^af UNIVERSITY HEALTH NETWORK   (Canada)

^ag MOUNT SINAI HOSPITAL   (Canada)

^ah UNIVERSITY OF TORONTO   (Canada)

^ai LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^aj UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^ak UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^al KUOPIO UNIVERSITY HOSPITAL   (Finland)

^am UNIVERSITY OF EASTERN FINLAND   (Finland)

^an NATIONAL CANCER INSTITUTE   (Italy)

^ao FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^ap UNIVERSITY OF HEIDELBERG   (Germany)

^aq ERASMUS MEDICAL CENTER   (Netherlands)

^ar ERASMUS MC CANCER INSTITUTE   (Netherlands)

^as NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^at DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^au UNIVERSITY OF LEUVEN   (Belgium)

^av UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^aw ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^ax GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^ay UNIVERSITY OF COPENHAGEN   (Denmark)

^az ROSWELL PARK CANCER INSTITUTE   (United States)

^ba QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^bb CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^bc UNIVERSITÉ PARIS SACLAY   (France)

^bd HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^be MAYO CLINIC   (United States)

^bf UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Association study; Common variants; Ductal carcinoma in situ; Genetic predisposition

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; CCND1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR PROTEIN;

ALLELE; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SUSCEPTIBILITY; CYCLIN D1 GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; INTRADUCTAL CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ADULT; AGED; BREAST TUMOR; FEMALE; GENETIC ASSOCIATION STUDY; GENETICS; GENOTYPE; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLIN D1; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84957951400     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0675-7     Document Type: Article

References (32)

1. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to. Cancer Epidemiol Biomarkers Prev. 2001;14(4):1008-11.
2. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96(12):906-20.
3. Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Brit J Cancer. 2010;102(9):1391-6.
4. Ruszczyk M, Zirpoli G, Kumar S, Bandera EV, Bovbjerg DH, Jandorf L, et al. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses. Cancer Causes Control. http://dx.doi.org/10.1007/s10552-015-0696-z.
5. Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006;106(10):2104-12.
6. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005;103(9):1778-84.
7. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478-88.
8. Pinder SE. Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol. 2010;23 Suppl 2:S8-13.
9. Aguiar FN, Mendes HN, Bacchi CE, Carvalho FM. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. Rev Bras Ginecol Obstet. 2013;35(3):97-102.
10. Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol. 2001;115(5):709-18.
11. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 2001;93(23):1811-7.
12. Reeves GK, Pirie K, Green J, Bull D, Beral V, Million Women Study C. Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. 2012;131(4):930-7.
13. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat. 2003;78(1):7-15.
14. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89(1):76-82.
15. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293(8):964-9.
16. Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 2014;10(4):e1004285.
17. Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 2014;35(5):1012-9.
18. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392-8. 398e391-392.
19. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353-61. 361e351-352.
20. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genome wide association scans. Bioinformatics. 2010;26(17):2190-1.
21. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012;21(24):5373-84.
22. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009;133(1):15-25.
23. Milne RL, Goode EL, Garca-Closas M, Couch FJ, Severi G, Hein R, et al. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2222-31.
24. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087-93.
25. Campa D, Barrdahl M, Gaudet MM, Black A, Chanock SJ, Diver WR, et al. Genetic risk variants associated with in situ breast cancer. Breast Cancer Res. 2015;17:82.
26. Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menendez-Rodriguez P, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2014;23(22):6096-111.
27. Thomas J, Hanby A, Pinder S, Ellis I, Macartney J, Clements K, et al. Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. Breast J. 2008;14(1):33-8.
28. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008;4(4):e1000054.
29. Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, et al. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Hum Mol Genet. 2014;23(22):6034-46.
30. Lambrechts D, Truong T, Justenhoven C, Humphreys MK, Wang J, Hopper JL, et al. 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat. 2012;33(7):1123-32.
31. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, et al. Functional variants at the 11q13 risk locus for breast cancer regulate Cyclin D1 expression through long-range enhancers. Am J Hum Genet. 2013;92(4):489-503.
32. Arvold ND, Punglia RS, Hughes ME, Jiang W, Edge SB, Javid SH, et al. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012;118(24):6022-30.